Stock Price & Analysis

Buy PCVX stock as analysts maintain a Strong Buy consensus with a $147.17 price target. Sell PCVX stock if concerned about its negative earnings and insider selling activity.

The price prediction for PCVX stock in 2025 is expected to range between $66 and $85. This forecast is based on current technical indicators, with the stock facing resistance at higher levels and support at lower levels.

The S1 support level for PCVX Stock is $68.67 ,The R1 resistant level for PCVX Stock is $75.77.

As of the end of day on 2025-03-19, the price of PCVX Stock was $74.5.

The target price for PCVX Stock according to analyst rating is 149.43, with the highest price target at 163.00 and the lowest at 135.00. Analysts have a Strong Buy rating on PCVX Stock overall.

The market cap of PCVX is $9.3B.

PCVX is likely overvalued given its negative earnings per share (EPS) and lack of revenue generation. The company reported zero revenue and negative net income across all four quarters of 2024, with EPS ranging from -0.85 to -1.01. Additionally, the gross margin remains negative, indicating operational inefficiencies. The stock's current price of $75.29 appears disconnected from its fundamentals, as there is no positive earnings or revenue to justify the valuation. Investors should exercise caution, as the lack of profitability and high valuation multiples suggest significant downside risk.

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Price Prediction for PCVX Stock by 2030

Based on current trends and analyst expectations, PCVX stock is predicted to reach $140 to $160 by 2030. This forecast is supported by the company's strong position in the healthcare sector, positive analyst sentiment, and long-term growth potential.

PCVX has a total of 254 employees.